参考文献/References:
[1] Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J,2023,44(37):3503-3626.
[2] 中华医学会心血管病学分会影像学组,中国医师协会放射医师分会心血管专业委员会. 无创性心血管影像学技术临床适用标准中国专家共识[J]. 中华心血管病杂志,2020,48(11):906-921.
[3] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice Guidelines[J]. Circulation,2020,142(25):e558-e631.
[4] Cui L,Tse G,Zhao Z,et al. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm:an important subtype of arrhythmogenic cardiomyopathy[J]. Ann Noninvasive Electrocardiol,2019,24(5):e12638.
[5] Liu J,Zhao S,Yu S,et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy[J]. Radiology,2022,302(2):298-306.
[6] Reiter U,Reiter C,Kr?uter C,et al. Cardiac magnetic resonance T1 mapping. Part 2:Diagnostic potential and applications[J]. Eur J Radiol,2018,109:235-247.
[7] Robinson AA,Chow K,Salerno M. Myocardial T1 and ECV measurement:underlying concepts and technical considerations[J]. JACC Cardiovasc Imaging,2019,12(11 Pt 2):2332-2344.
[8] O’Brien AT,Gil KE,Varghese J,et al. T2 mapping in myocardial disease:a comprehensive review[J]. J Cardiovasc Magn Reson,2022,24(1):33.
[9] Sipola P,Magga J,Husso M,et al. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation[J]. Eur Radiol,2011,21(7):1383-1389.
[10] Cionca C,Zlibut A,Agoston-Coldea L,et al. Advanced cardiovascular multimodal imaging and aortic stenosis[J]. Heart Fail Rev,2022,27(2):677-696.
[11] Martinez-Naharro A,Kotecha T,Norrington K,et al. Native T1 and extracellular volume in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2019,12(5):810-819.
[12] Ponsiglione A,Gambardella M,Green R,et al. Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease:a systematic review and meta-analysis[J]. J Cardiovasc Magn Reson,2022,24(1):31.
[13] Boentert M,Florian A,Dr?ger B,et al. Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease:a comprehensive cardiovascular magnetic resonance approach[J]. J Cardiovasc Magn Reson,2016,18(1):91.
[14] Miliou A,Antonopoulos AS,Kouris N,et al. Danon cardiomyopathy:specific imaging signs[J]. JACC Case Rep,2022,4(22):1496-1500.
[15] Maron BJ,Rowin EJ,Maron MS. Paradigm of sudden death prevention in hypertrophic cardiomyopathy[J]. Circ Res,2019,125(4):370-378.
[16] Chan RH,Maron BJ,Olivotto I,et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy[J]. Circulation,2014,130(6):484-495.
[17] Briasoulis A,Mallikethi-Reddy S,Palla M,et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy:a meta-analysis[J]. Heart,2015,101(17):1406-1411.
[18] Zeppenfeld K,Tfelt-Hansen J,de Riva M,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43(40):3997-4126.
[19] Avanesov M,Münch J,Weinrich J,et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR[J]. Eur Radiol,2017,27(12):5136-5145.
[20] Xu J,Zhuang B,Sirajuddin A,et al. MRI T1 mapping in hypertrophic cardiomyopathy:evaluation in patients without late gadolinium enhancement and hemodynamic obstruction[J]. Radiology,2020,294(2):275-286.
[21] Harris KM,Spirito P,Maron MS,et al. Prevalence,clinical profile,and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy[J]. Circulation,2006,114(3):216-225.
[22] Maron BJ,Rowin EJ,Udelson JE,et al. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy[J]. JACC Heart Fail,2018,6(5):353-363.
[23] O’Hanlon R,Grasso A,Roughton M,et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):867-874.
[24] Ellims AH,Iles LM,Ling L,et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging:linking genotype with fibrotic phenotype[J]. Eur Heart J Cardiovasc Imaging,2014;15(10):1108-1116.
[25] Schuster A, Hor KN, Kowallick JT,et al. Cardiovascular magnetic resonance myocardial feature tracking:concepts and clinical applications. circulation cardiovascular imaging[J]. Circ Cardiovasc Imaging,2016,9(4):e004077.
[26] Cau R,Bassareo P,Suri JS,et al. The emerging role of atrial strain assessed by cardiac MRI in different cardiovascular settings:an up-to-date review[J]. Eur Radiol,2022,32(7):4384-4394.
[27] Vigneault DM,Yang E,Jensen PJ,et al. Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy:cardiac mr feature tracking[J]. Radiology,2019,290(3):640-648.
[28] Yang Y,Yin G,Jiang Y,et al. Quantification of left atrial function in patients with non-obstructive hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking imaging:a feasibility and reproducibility study[J]. J Cardiovasc Magn Reson,2020,22(1):1.
[29] Hinojar R,Fernández-Golfín C,González-Gómez A,et al. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis[J]. Int J Cardiol,2017,249:467-472.
[30] Bissell MM,Raimondi F,Ait Ali L,et al. 4D Flow cardiovascular magnetic resonance consensus statement:2023 update[J]. J Cardiovasc Magn Reson,2023,25(1):40.
[31] Ashkir Z,Johnson S,Lewandowski AJ,et al. Novel insights into diminished cardiac reserve in non-obstructive hypertrophic cardiomyopathy from four-dimensional flow cardiac magnetic resonance component analysis[J]. Eur Heart J Cardiovasc Imaging,2023,24(9):1192-1200.
[32] Dai Z,Iguchi N,Takamisawa I,et al. Alcohol septal ablation markedly reduces energy loss in hypertrophic cardiomyopathy with left ventricular outflow tract obstruction:A four-dimensional flow cardiac magnetic resonance study[J]. Int J Cardiol Heart Vasc,2021,37:100886.
[33] Khalique Z,Ferreira PF,Scott AD,et al. Diffusion Tensor Cardiovascular Magnetic Resonance Imaging:A Clinical Perspective[J]. JACC Cardiovasc Imaging,2020,13(5):1235-1255.
[34] Das A,Kelly C,Teh I,et al. Phenotyping hypertrophic cardiomyopathy using cardiac diffusion magnetic resonance imaging:the relationship between microvascular dysfunction and microstructural changes[J]. Eur Heart J Cardiovasc Imaging,2022,23(3):352-362.
[35] Ariga R,Tunnicliffe EM,Manohar SG,et al. Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias[J]. J Am Coll Cardiol,2019,73(20):2493-2502.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(2):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(2):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(2):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(2):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(2):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(2):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[10]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(2):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]